
    
      This is an open-label (volunteers will know the names of treatments they are assigned)
      single-center and cross-over study of SP2086 and Glyburide in healthy adult volunteers. All
      subject were randomized into two groups, and the drugs will be administered according to the
      AB and BA sequences.The A sequence was that Glyburide was taken at 5mg qd dose on
      Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B
      sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8; Glyburide will be
      administered orally (by mouth) as 200mg on Days 8.
    
  